Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015, Article ID 475630, 6 pages
Clinical Study

Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson’s Disease

1Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain
2Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
3Epilepsy Unit, Department of Neurology, Hospital Clínic, Barcelona, Catalonia, Spain
4Neurology Service, Clínica Dexeus, Barcelona, Catalonia, Spain
5Neurology Service, Hospital de Terrassa, Barcelona, Catalonia, Spain
6Cap Clìnic de Neurologìa, Hospital Universitario Reus and Department of Medicine and Surgery, Universitat de Tarragona, Tarragona, Catalonia, Spain
7Neurology Service, Parc Sanitari Sant Joan de Déu, Sant Boi, Barcelona, Catalonia, Spain
8Neurology Service, Hospital Parc Taulí de Sabadell, Catalonia, Spain
9Clínica Juaneda, Palma de Mallorca, Balearic Islands, Spain

Received 4 August 2015; Accepted 30 September 2015

Academic Editor: Ivan Bodis-Wollner

Copyright © 2015 Francesc Vallderiola et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objectives. This open-label study assessed the efficacy and safety of exclusive night-time administration of transdermal rotigotine in patients with nocturnal and early morning PD symptoms. Methods. Patients with PD and nocturnal and early morning symptoms received transdermal rotigotine patches (2–16 mg/24 h) applied in the evening and removed in the morning for 3 months. Sleep disturbance was assessed with modified Parkinson’s Disease Sleep Scale (PDSS-2). Other outcomes included a pain visual analogue scale (VAS) and short-form Parkinson’s Disease Questionnaire (PDQ-8) for quality of life. Results. 74 patients completed treatment in this study. At the end of treatment, PDSS-2 total score had improved by mean 10.9 points from baseline (p < 0.001). All three PDSS-2 domain scores (sleep disturbances, nocturnal motor symptoms, and nocturnal symptoms) were also significantly improved by 41%, 56%, and 48%, respectively (p < 0.001). VAS-pain score decreased from 3.2 to 2.3 (p < 0.001). PDQ-8 score decreased from 23.8 to 18.1 (p < 0.001). The most frequently reported adverse events included nausea (9%), anxiety (4%), and dizziness (4%). Conclusions. Night-time administration of transdermal rotigotine is an effective and well tolerated treatment for nocturnal symptoms in patients with PD.